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ABSTRACT 
The radioimmunoa.ssay of insulin according to the method of 
Hales and Randle (56) was the basis of our studies. In the 
method, bovine albumin, (Fraction V powder), was used in all 
buffers, in concentrations from 0. 1% to 3. 9%. Investigators 
have reported making effects of insulin activity by bovine and 
human albumin preparations, in concentrations from l. ZS% to 
5. 5%. To avoid this, polyvinylpyrrolidone, molecular weight 
40, 000, was substituted for albumin in all buffers, with no ap-
parent loss of accuracy. Since PVP may be kept at room temper-
ature, and la more easily dissolved than albumin, the prepara-
tion of the buffers is simplified and the substitution decreases 
the cost of the assay. 
Problems were al so incurred with the cellulose acetate 
membranes used in the assay procedure, due to the non-uniform 
retention of free labeled insulin by the membranes. Gelman 
membranes #GA 6, O. 45 U M were found to give the best re-
sults, the retention of the free labeled insulin being much lower 
and much more uniform. Wash control samples varied from 14 7 
to Z35 CPM (less background) with a standard deviation of 22. 9 
for five replicates. 
Changes in the scintillation system were also employed, allow-
ing the use of a much less complicated fluor than originally used, 
with no apparent loss of accuracy or efficiency. 
The final modified assay procedure was used to determine the 
activity of "bound" insulin extracts, prepared according to the method 
of Antonia.des (25), with and without the presence of sodium tolbuta-
mide. Sodium tolbutamide has been reported by some investigators 
to have extra.pancreatic effects, particularly the release of biologi-
cally active insulin from circulating insulin complexes. 
In our own work, ''bound" insulin extracts, exhibiting very low 
amounts of insulin activity in the absence of sodium tolbutamide, 
exhibited significant amounts of insulin activity when incubated for 
two hours at 37°C with sodium tolbutamide. This is a significant 
finding, for it strongly substantiates the claim of extra.pancreatic 
effects of tolbutamide; it also lends credence to the findings of 
Antonia.des concerning "bound" insulin, for his assay methods de-
pended on the biological action of insulin on muscle or adipose tissue. 
In these assays, other factors may be acting to mimic the effect of 
insulin, and th ere is no guarantee that true insulin is being 
measured; but in the radioimmunoassay, the measurement of insulin 
activity depends on the structure and conformation of the insulin 
molecule, and is not aubject to mimic effects from other !actors. 
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CHAPTER I 
DIABETES lv1ELLITUS AND ITS W...ETABOLIC EFFECTS 
Introduction 
The first recorded description of tb.e condition known as dia-
betes is found in the writings of a Roman, Aretaeus the Cappado-
cian, around 100 A. D. He described it as a "melting down of the 
flesh and limbs into urine. 11 .From this observation, he attributed 
the disease to a malfunction of the kidneys and bladder; hence the 
name "diabetes 11 , meaning literally ''to pass through 11 • Since that 
time, of course, the art of medicine has progressed immensely, 
and our present knowledge of the disease is much more sophisticated, 
although far from complete. The study of diabetes has grown to be 
most complex, with many methods avail.able for monitoring and con-
trolling the course of the disease. The symptomatology of the dis-
ease is itself a very complex one, with many variations in the man-
ifestation of the diabetic state: juvenile-onset, adult-onset, insulin-
dependent, non-insulin-dependent, ketotic, et cetera. Even more 
cornplex is the study of the metabolic changes accompanying the 
disease. All phases of metabolism are affected in some way in the 
diabetic state. Changes in carbohydrate, protein, and lipid metab-
olism all manifest themselves in the course of diabetes. 
-1- ,i 
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Carbohydrate Metabolism 
Deficiencies in carbohydrate metabolism are the most 
closely allied metabolic abnormalities associated with the diabetic 
state. In fact, the elevated level of blood sugar, which has be-
come the classical indication of diabetes, is due to an impairment 
in normal glucose metabolism. It is here that insulin normally 
plays an important role, acting in the first step of the conversion 
of glucose into its metabolites, the step resulting in the production 
of glucose-6-phospbate. The action of insulin in this step is con-
sidered to be twofold: (1) It acts directly on the hexokinase system, 
increasing the synthesis and availability of the enzyme necessary 
for the conversion; (Z) Insulin acts to enhance the production of 
glucose-6-phosphate by a transport mechanism in which the insulin 
acts as a carrier for transporting the glucose across the cell 
membrane, across a concentration gradient. In the diabetic state, 
(that is, one in which the insulin is not present in sufficient quan-
tity, at least, not in the biologically active form), the glucose 
I 
' 
transport system cannot function properly, and the overall metab-
olism of glucose is impaired. This in turn causes a build-up of 
'I 
glucose in the extracellular fluid, and gives rise to the observed ! II 
elevation in blood sugar. 
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FIGURE I 
ABNORMAL CARBOHYDRATE METABOLISM IN 
DIABETES MELLITUS 
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Lipid Metabolism 
Along with the abnormalities in carbohydrate metabolism ob-
served in the diabetic state, there are four major abnormalities in 
lipid metabolism associated with the disease. 
The first abnormality is the impaired biosynthesis of fatty 
acids, first demonstrated by Stetten and Boxer {l), who reported de-
creased incorporation of deutrium-labeled water into fatty acids in 
intact and diabetic rate. Also, Chaikoff (Z) reported similar findings 
using 14-C-labeled glucose, in intact and alloxa.n diabetic rats. 
Of course, the very fact that glucose metabolism is disturbed 
would account for a concomitant decrease in fatty acid synthesis, 
since glucose is a prime source of fatty acids, as shown in Figure II. 
However, it has been shown that the deficiency in fatty acid synthesis 
is more severe than can be accounted for by this fact alone. The 
synthesis of fatty acids from substances other than glucose, such as 
fructose, has been demonstrated to be impaired in the diabetic 
state (3). 
The second deficiency in lipid metabolism accompanying dia-
betes is an increased level of fatty acid oxidation. Lossow and co-
workers (4) have shown direct evidence for an increased rate of oxi-
dation of fatty acids to carbon dioxide in the diabetic • The direct re -
lationship of this fact to glucose oxidation was also shown, since the 
-4-
injection of glucose in normal animals, or the administration of 
insulin to diabetics, results in a rapid decrease in fatty acid oxi-
dation. 
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FIGURE 11 
ABNORMAL LIPID METABOLISM IN DIABETES MELLITUS 
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A third abnormal condition in lipid metabolism accompany-
ing diabetes is ketosis. The development of this condition can be 
seen in the following summary, and in Figure III. The diabetic 
must rely on increased fat oxidation for energy, providing acetyl 
CoA in sufficient amounts, but resulting in a lack of pyruvate and 
NADPH. Thus, the Kreb's cycle cannot function properly, and 
the acetyl CoA is shunted into the production of B-hydroxy-B-methyl 
glutaryl CoA, and into the synthesis of ketone bodies (acetone, 
acetonacetate, and B-hydroxybutyrate). 
Lastly, it bas been found that cholesterol levels are elevated 
in the blood of diabetics (5). There is also much evidence for the 
implication of high cholesterol levels in atherosclerosis (6). Com-
bined with the almost "normal" incidence of atherosclerosis in dia-
betics, the elevated cholesterol found in diabetic blood is a problem 
of utmost concern. 
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FIGURE III 
PRODUCTION OF KETONE BODIES IN DIABETES MELLITUS 
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PROTEIN METABOLISM 
The third major metabolic effect of diabetes is on protein 
metabolism. The lack of insulin and the resulting inability to 
metabolize glucose causes a net decrease in protein synthesis, 
especially in muscle tissue, with its high demand for a source of 
energy. This decrease is accompanied by an elevated level of 
amino acids in the circulation, which in turn are used either to form 
glucose, or to form ketone bodies, which are already in excess from 
the pathway described in the discussion of lipid metabolism. 
DISCUSSION 
The effects of the lack of insulin on the body are not limited 
to those described above, by any means. In addition to, and direct-
ly related to, the defects in carbohydrate, lipid, and protein metab-
olism, the lack of insulin also results in other related maladies, 
such as electrolyte imbalance, dehydration, hemoconcentration, 
acidosis, peripheral circulatory failure, and many other serious 
problems. The major difficulties observed in and related to dia-
betes, as well as their interrelationships, are listed in Figure IV. 
This list is not meant to be comprehensive, but it serves to demon-
strate the norm.al course of the disease. 
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r FIGURE fV 
SUMMARY OF METABOLIC AND PHYSIOLOGICAL EFFECTS 
OF DIABETES MELLITUS 
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Loss of 
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CHAPTER II 
DIABETES AND BLOOD INSULIN LEVELS 
History 
The prime factor in diabetes mellitus is, without a doubt, 
that of a deficiency in insulin action. Whether this deficiency is 
always due to a lack of insulin production by the pancreas, or some 
lack of expression of insulin activity in extrapancreatic tissue, is 
not known. In fact, the development of methods for assaying insulin 
levels in the blood has led to many interesting theories on the true 
state of the hormone in the circulation, and the relation of the level 
of circulating hormone to the level of biologically active material. 
Historically, the first idea that linked diabetes to the pancreas 
was proposed by Banting in 1929 (7), who suggested that the disease 
was due to "a deficiency of the internal secretion of the pancreas, 
although we do not know the cause of the deficiency. " At that time, 
no relationship between diabetes and blood insulin levels had been 
established, due to the fact that only crude methods of determining 
insulin concentration were available. For quite a long period of 
time, this situation did not change. Until the early 1950 1s, not very 
much was known about the mode of transport of insulin in the body, 
although its physiological properties were fairly well established. 
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In 1951, Bornstein and Lawrence (8), working in London, 
studied the effects of injections of human serum into hypophysecto-
mized, adrenalectomized rats, rendered diabetic by destruction of 
the pancreatic beta cells with allo.xan. They reported three very 
interesting findings. First of all, they found that serum from nor-
mal fasting humans had the same blood-glucose lowering effect as 
50 uU/ml of crystalline insulin (One unit is defined as the a.mount 
of insulin activity contained in O. 0408Z mg of the International Stand-
ard Preparation; its physiological definition is the amount of insulin 
necessary to reduce the blood glucose level of a normal Z kilogram 
rabbit, afte1· a 24-hour fast, from 12.0 to 45 mg/100 ml. 
These investigators also found that serum from adult, insulin-
dependent diabetics currently under insulin control had approximately 
the same glucose lowering effect as normal serum. Finally, they 
reported that the serum from insulin-dependent juvenile diabetics 
had no hypoglycemic effect, and in some cases, made the rate re-
sistant to subsequent injections of crystalline insulin. 
While these findings were interesting and theoretically could 
be used as the basis of an assay method for insulin activity of serum, 
the problems encountered in maintaining adrenalectomized, hypophysec-
tomized rats alive, as well as the problems in reproducibility, made 
the method impractical as a standard assay for insulin. 
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Rat Diaphragm Muscle Assay 
In 1954, Vallance-Owen and Hurlock(9) studied the addition 
of insulin to a glucose-containing medium, incubated with isolated 
rat diaphragm muscle. They found that the insulin stimulated glu-
cose uptake and glycogen deposition in the muscle tissue. They used 
this as the basis of the first reliable assay of insulin activity, sensi-
tive to amounts of insulin as low as ZS-50 uU/ml. Using this assay 
method, Vallance-Owen(lO), as well ae other investigators (11). re-
ported that the serum of uncontrolled insulin-dependent diabetics ex-
hibited no insulin activity, while the serum of controlled insulin-de-
pendent diabetics had normal, even excessive amounts of insulin-
activity. This led to the postulation that in some cases of diabetes, 
insulin may be present in sufficient quantities to handle a glucose 
load in a normal situation, but that some form of antagonist to lnsu-
lin was preventing the eJ4>resaion of the full biological activity of the 
hormone. 
Rat Epididymal Fat Pad Assay 
Another reliable assay of insulin activity was developed by 
Renold and coworkers in 1958 (12). Their assay was based on the 
addition of insulin to rat epidldymal fat pad in a suspending medium; 
they observed accelerated glucose uptake, increased oxidation of glu-
coae to carbon dioxide, and increased incorporation of glucose into 
glycogen and lipids. 
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In general, the values obtained from normal human serum 
were higher with the fat pad assay, ranging from values of 33 to 
940 uU /ml, with a mean of 290 uU /ml, than were the normal values 
reported with the diaphragm muscle assay of Vallance -0\.ven and Hur-
lock, with a range of 10 to 100 uU/ml, and a mean value of 57 uU/ml 
For this reason, the values reported using the fat pad assay were 
cautiously designated as insulin-like activity (ILA), to include the 
possibility that there may be some other factor besides insulin pro-
ducing the effects normally attributed to insulin. 
Renold and coworkers further reported (13) that the serum of 
severe, uncontrolled insulin-dependent diabetics, which bad exhibited 
no insulin activity when assayed by the rat diaphragm method, ex-
hibited high levels of ILA with the epididymal fat pad assay. This in-
troduced the possibility that adipose tissue bad some mechanism for 
the utilization of the substance exhibiting ILA, while no such mech-
anism was acting in muscle tissue. 
"Typical" and "Atypical" Insulin 
In 1955, Maloney and Coval (14), at the University of Toronto, 
produced a specific anti-insulin antibody serum, which abolished the 
biological effect of pure crystalline insulin when incubated with rat 
adipose tissue or rat diaphragm muscle. 
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But the anti-serum, when added to normal human serum, sup-
pressed only a part of the ILA in the fat pad assay, while suppress-
ing all the activity in the diaphragm assay. In subsequent studies, 
Slater and cowoekrrs (15) confirmed these findings and coined the 
terms 11typical 11 and "atypical" insulin, the "typical" form being the 
insulin suppressible by insulin anti-serum, and the "atypical" the 
form which is not suppressed by the' anti-serum. 
Samaan and coworkers (16) were able to separate the two forms 
of serum ILA using ultracentrifugation techniques. They reported 
that the "atypical" form bad a molecular weight in excess of 30, 000 
and that prolonged acid-ethanol extracti on of the ''atypical" form 
caused more than two-thirds of it to be converted to the "typical" 
form. 
An analysis of the relative amounts of "typical 11 and "atypical 11 
# 
insulin revealed the following: ''typical" insulin measured in pan-
creatic venous blood accounted for 90-95% of the total ILA, while in 
hepatic venous blood, ''typical 11 insulin represented only about 50% 
of the total ILA. From these findings, Samaan suggested that en-
dogenous insulin, produced in the pancreatic beta cells, was being 
altered in some way in the liver, rendering it inactive to insulin 
anti-serum, and resulting in the formation of "atypical 11 insulin. 
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-Froesch and coworkers (17), at the University of Zurich, 
used fractional precipitation, gel chromatography, and electro-
phoresis to isolate and partially purify "atypical" insulin. They were 
able to isolate a substance with non-suppressible ILA when assayed 
in either the rat diaphragm or adipose tissue assay method. It had 
an activity of only 2 uU/mg, compared to about 25 uU/mg for pure 
crystalline insulin. However, its properties were very similar to 
those of crystalline insulin. It induced hypoglycemia when injected 
into normal animals. It stimulated glucose uptake, lipid incorpora-
tion of, and carbon dioxide formation from glucose. It inhibited 
lipolysis in the absence of glucose. When passed through Sephadex 
G-75 in 5M acetic acid, a material was eluted which had a molecular 
weight of approximately 6, 000, resembling that of insulin under the 
same conditions. However, when oxidized with performic acid, no 
normal insulin A chain was found, using electrophoretic mobility as 
the identification method. 
This laat fact led Froeach to postulate that some change in 
the insulin A chain goes on in the liver, altering its physical 
properties so that large aggregates of individual molecules are 
formed. Under the proper conditions, these aggregates may dis-
aociate into units of the same molecular weight and biological 
activity as native insulin. 
-16-
- --------~------------------" 
Keen and coworkers (18, 19) studied extracts of plasma 
proteins using trichloroacetic acid precipitation, and TCA-ethanol 
extraction procedures. The fraction collected in this manner was 
con1.posed largely of serum albu1nin, and yet h.a.d many insulin-like 
properties. It increased glucose uptake and glycogen deposition by 
the isolated rat hemidiaphragm. It promoted incorporation of labeled 
amino acids into muscle protein. When incubated with fat pad, the 
extract accelerated glucose uptake and oxidation. and incorporation 
of labeled glucose into lipid. 
A large percentage of this activity expressed in the presence 
of fat pad was not suppressible by anti-insulin antibody. This fact 
links this fraction very closely with the extracts studied by Froesch. 
In 1960, Yalow and Berson (20) developed a very sensitive 
assay of insulin based on competition for antibody sites, in potent 
anti-insulin serum, between a known quantity of added, labeled in-
sulin and the insulin present in the plasma sample to be assayed. 
Estimates of activity using this radioimmunoassay are lower than 
those using the bioassays, particularly the fat pad assay. It is 
postulated that only the "typical" (suppressible) insulin-like activity 
is being measured in this assay. The method is reported to be 
specific for insulin,. and it is sensitive to amounts of insulin less 
than O. 01 uU/ml. 
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"Free 1' and 11Bound 11 Insulin 
Another very important interpretation of the separation of 
serum insulin into more than one component is the theory that the 
hormone may exist in the blood partially as free. biologically active 
material, along with a biologically inactive form of insulin, bound 
to some other plasma constituent&. Antoniades and coworkers (2.1) 
were using acid-ethanol precipitation of plasma in order to isolate 
a fraction with ILA. To prevent coagulation of the blood samples, 
one of two methods was employed. The blood was either treated 
with acid citrate dextrose, (ACD), or passed through a cationic ex-
change resin, to decalcify the samples, and thus inhibit coagulation. 
The samples preserved by the treatment with ACD had retained all 
of their insulin-like activity, but it was found that the samples 
treated with the cationic exchange resin had lost almost all its 
activity, measured by the rat diaphragm method. in the presence 
of adipose tissue. This lost activity was regained from the column 
by elution with dilute NH4 OH. 
Althoug_ .. the eluted substance had no effect on rat diaphragm, 
it was found to possess considerable ILA when assayed by the fat 
pad assay, or by the diaphragm assay in the presence of adipose 
tissue. If the eluted material was first incubated with saline ex-
tracts of adipose tissue, it regained the ability to stimulate glucose 
-18-
uptake by the diaphragm (22). This regained activity was found by 
Shaw and Shuey (23) to be inhibited completely by anti-insulin serum, 
indicating that there was true insulin in the resin eluate. 
These results, along with the results of other studies in his 
own laboratories (24, 25, 26) led Antoniades to postulate that the ILA 
retained by the resin was a form of native insulin, complexed with 
a basic protein. He felt that the actual binding of the insulin to 
the resim could only be explained by means of this basic protein 
complex. Since insulin itself, at physiological pH, is . negatively 
charged, and since human insulin migrated electrophoretically as an 
anion, the fact that it is adsorbed onto a cationic exchange resin 
indicates that the insulin in the blood may be transported along with 
a substance having a higher isoelectric point, most likely a protein. 
Antoniades further postulated that the fat pad e4"tract was 
somehow able to dissociate the insulin-protein complex, and restore 
normal ("typical", suppressible) activity to the insulin (27). 
In studies conducted to determine the relative amounts of the 
two forms of insulin, which Antoniades termed "free" and "bound 11 , 
in human serum, he reported (28, 29, 30) that an equilibrium existed 
between the two for ms of insulin. and that the equilibrium was 
shifted toward the "free" form upon ingestion of a glucose load. In 
1
1 
the case of some diabetics, it was postulated that one of their main 
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problems n1i6ht well be an inability to convert the corn.plexed or 
11bound 11 insulin to the "free 11 form with enough rapidity, or to a 
great enough extent, to handle the glucose load, leading to an ob-
served deficiency in total insulin activity, 
Electrophoretic techniques were employed to locate the frac-
tions of normal human serum exhibiting ILA, by the bioassay of the 
fractions separated on the basis of their mobilities (31). Some en-
dogenous insulin and all added, labeled insulin was found to migrate 
with the albumin fraction and the 0( l fraction. This endogenous 
insulin is postulated to represent the "free" insulin in plasma, since 
pure crystalline insulin, when run separately, migrated to a similar 
position. A second site of substantial ILA was found, again measured 
by bioassay, corresponding to the (3 •globulin region. Added labeled 
insulin was not found to migrate to this position. Therefore, it was 
postulated that this ILA could correspond to the "atypical" or "bound 11 
insulin. 
Further characterization studies of the insulin-protein com-
plex were undertaken by Antoniades (31). The resin extracted com• 
plex was eluted with dilute ammonium hydroxide, and then either 
incubated with rat adipose tissue, or subjected to centrifugation at 
pH 9. 8, to try to release the "free" insulin from the complex. As 
had been the case in previous studies. the adipose tissue caused a 
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release of IL.A from the cornplcx. It was also found that at 
pH 9. 8, the basic protein r~-0cipitated, and the "free" insulin was 
detectable in the supernatant after centrifugation. 
The effects of dialysis on the complex were also studied (32). 
Dialysis of the resin eluate after either weak acid or base elution 
had an effect on the ILA. Undialysed samples exhibited higher 
levels of activity than samples dialysed against sodium chloride for 
from twelve to twenty-four hours. This was interpreted by Anton-
iades to indicate that the insulin complexes may recombine slowly 
at neutral pH. Dialysis of the resim eluates at acid pH(Z. 0 to 3.D) 
did not free the complex. 
Concentrates of the insulin-binding protein were prepared by 
subjecting the resin eluates to centrifugation at pH 9. 8. The col-
lected precipitates were pooled, dissolved in acetate buffer at 
pH 4. 0, and subjected to paper electrophoresis in phosphate buffer 
at pH 7. 4 for sixteen hours at room temperature. One substance 
only was evident, and it appeared to have a substantial positive 
charge, suggesU.na that it was indeed basic in nature. The protein 
did not pass through a cellophane membrane at pH 3. 0 or 7. 0, indi-
cating a relatively large molecular weight. Its isoelectric point 
was considered to be in the region of pH 9. 8, since it was at this 
pH that it dissociated from the insulin, and was removed as the 
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precipitate upon centrifugation. 
Attempts were made to form the insulin complex !!!_. ~ 
by incubating insulin labeled with iodine-131 with serum samples. 
No complexes were found, measured by loss of detectable insulin 
activity, after incubation d s0 c and zs0 c for from five minutes to 
twenty-four hours. Thia suggested that either there is no large 
amount of free insulin-binding protein circulating in the blood, or 
that the formation of the complex is of a more complex nature, and 
could not be duplicated in a simple incubation. 
The dlasociation of the insulin-protein complex upon incuba-
tion with adipose tissue extracts in vitro was studied by Antoniades 
and Gundersen (27). Lyophilized resin eluates were dissolved in a 
physiological buffer at a concentration of fifteen milligrams of resin 
eluate per milliliter of buffer. One set of samples was assayed by 
the rat diaphragm method, without the addition of adipose tissue 
extracts. Identical portions were assayed in the presence of adipose 
tissue extracts (O. 5 to l. 0 ml of extract added to 10 ml of incubation 
medium). In all cases, the presence of the adipose tissue extracts 
caused a release of the ILA from the resin eluates. Additional 
experiments were performed to determine the effect of varying the 
concentration of the adipose tissue extracts on the amount of ILA 
released. It was found that a crude saline extract with a nitrogen 
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content of 18 ug/ml of incubating medium was adequate to stimulate 
the release of all the available insulin. 
This evidence seems to indicate the possibility of an activat-
ing mechanism in adipose tissue which enhances the utilization of 
the insulin-protein complex, possibly by altering the rate of 
dissociation of the complexed form, and thereby increasing the 
amount of "free 11 insulin available for utilization. 
In vivo studies (33) have indicated that adipose tissue ex-
tracts produce hypoglycemia in insulin-sensitive animals, using 
intrave 1ous or intraperitoneal administration of partially purified 
adipose tissue extracts, from rat or bovine adipose tissue. Pre -
liminary studies by Antonia.des on the nature of the active factor 
in the extracts indicate that it is heat stable and bas a molecular 
eight below 1, 000(34). 
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CHAPTER m 
INSULIN ANTAGONISM 
According to Vallance -Owen, an insulin antagonist is any 
substance or fraction which can modify or combine with insulin 
to render it inactive or counteract its effects in vivo or in vitro (35). 
Several known substances and some as yet unidentified factors have 
been shown to exhibit an antagonistic effect on insulin. Growth 
hormone, epinephrine, and the adrenal cortical steroids are insulin 
antagonists, due to their ability to raise blood sugar levels (36, 37). 
The antibodies that are commonly used in the radioimmunoassay of 
insulin a.re insulin antagonists. They often appear in the blood of 
diabetics who have been under insulin control for an extended period 
of time, and they cause insulin resistance in those patients (38). 
Non-esteri£ied fatty acids have been implicated as insulin antagonists, 
due to their ability to impair glucose uptake in isolated muscle 
tissue of the rat (39). Elevated levels of non-esterified fatty acids 
have been shown to be an early marker in the course of diabetes (40). 
Vallance-Owen and Hurlock (41) have reported an insulin 
antagonist present in preparations of the albumin fractions of plasma 
proteins of both normal and diabetic subjects. At concentrations 
of 3, 5 to 5. 5%, both diabetic and normal albumin preparations com-
pletely inhibited the effect of 1, 000 uU/ml of insulin in vitro. This 
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range includes the normal physiological concentration of albumin. 
At a lower concentration, around I. 25%, only the diabetic albumin 
was effective as an antagonist. After passage through a partially 
acetylated cellulose column, the albumin from both normal and dia-
betic serum had lost all its ability to act as an antagonist, although 
it remained electrophoretically identical to albumin. The name 
"synalbumin 11 has been coined in reference to the antagonist, indicatin~ 
that the antagonism is apparently due to some other factor associated 
with the albumin, and not to the albumin itself. The antagonistic 
effect is not present in albumin preparations from hypophysectomized 
subjects, and has been shown to depend on the presence of adrenal 
corticosteroids (42). 
It bas also been demonstrated that the albumin of pre-diabetics 
is antagonistic at 1. 25%, while the albumin of normal subjc :::ts, as 
was mentioned earlier, was not antagonistic. This fact has been 
suggested as the basis of a possibly useful diagnostic test for the 
early stages of diabetes (43). 
The insulin antagonist in albumin preparations has been shown 
to have a molecular weight of just under 4, 000. With this in mind, 
and with the fact that in many cases a metabolite of an. active com-
pound may inhibit the action of that compound, the possibility that 
the insulin B-chain may be related to the antagonist was considered, 
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for the following reasons. The B-chain of insulin has a molecular 
weight of 3, 800, and is insoluble in phyaiological solutions in the 
reduced state. It bas been found to migrate electrophoretically 
with albumin, bound to the albumin, and in this state it is soluble 
in physiological solutions (44). 
The albumin·B-cbain complex, prepared in vitro using non-
antagonistic album.in incubated with small amounts of B-chain, ex-
hibits a high degree of antagonistic activity in the rat diaphragm 
assay (45). If it can be shown definitely that the insulin B-cbain is 
identical to the "synalbumin" antagonist, as Vallance-Owen postulates, 
then one of the main problems in the diabetic state may be a high 
level of circulating B:-ebain, possibly due to an insulin degradation 
proceas taking place in the liver or some other extrapancreatic 
tissues. 
-26-
CHAPTER IV 
THE ACTION OF TOLBUTAMIDE 
Since insulin is protein in nature, it is subject to attack 
from the proteolytic enzymes in the digestive system, resulting 
in subsequent lose of biological activity. For this reason, insulin 
must be administered via injection if it is to serve as a beneficial 
aid in the treatment of diabetes. Since the need for the daily in-
jection of insulin causes obvious difficulties for the patient, re-
searchers have long been seeking a subatitute for insulin that could 
be administered orally, and thus alleviate much of the danger and 
discomfort inherent in insulin therapy. 
The first reports of a possible insulin substitute date back 
to 1926, when the hypoglycemic effect of the biguanide synthalin 
was reported (46). However, this compound was useless as an 
inaulin substitute because of its high degree of toxicity, resulting 
in severe liver damage (47). 
Many other compounds were studied, moat of them plant 
derivatives, but along with the desired hypoglycemic action, they 
were all found to be too toxic for use in diabetes therapy. In 1942(48), 
a synthetic compound was reported to have hypoglycemic effects, and 
although it was found to be toxic, it paved the way for the develop-
ment of other synthetic compounds with possible use ae oral hypo-
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glycemic agents. Since that time, a wide variety of compounds 
has been examined, including the tiadiazoles, sulfonylureas, and 
guanidine derivatives, the most success having been enjoyed with the 
arylsulfonylureas. Although most of the compounds studied were 
found to be too toxic for long-term use, two of them have been sub-
jected to extensive clinical examination, and found to be suitable for 
the management of the milder cases of adult diabetes mellitus. 
The most widely accepted compound in this class of oral hy-
poglycemic a.gents is tolbutamide, or more properly, the sodium salt 
of tolbutamide. It was the first sulfonylurea to be marketed in the 
United States as a therapeutic agent for the management of diabetes. 
The primary action of tolbutamide is the stimulation of the 
pancreatic beta cells to secrete insulin (49). It bas been demon-
strated that patients with mild cases of maturity-onset diabetes do 
not have an absolute insulin deficiency; rather, when subjected to a 
glucose load, they respond with a very slow rise in plasma insulin 
levels, followed by a much delayed peak, and slow decline (50). 
Whereas a normal subject will react very quickly to a glucose load 
with an immediate release of a small amount of insulin, the diabetic 
will respond with much more slowly, with an eventual rise in plasma 
insulin levels that equals or exceeds that of the normal subject. 
Treatment with tolbuta.mide bas been shown to return the insulin 
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response to a glucose load to one more closely resembling the 
normal conditions(Sl). The main interpretation of the mode of action 
of this change in response has been that the tolbutamide releases 
insulin from the pancreas into the circulation and in this way allows 
the patient to respond normally to the glucose load. 
Evidence for a dual action of tolbutamide has been presented 
by a few investigators. Antoniades(52) has reported that in addition 
to the stimulation of insulin release from the pancreas, tolbutamide 
increases the rate of utilization of the inactive form of circulating 
insulin in non-diabetic and non-insulin-dependent diabetics. Intra-
venous administration of tolbutamide in these subjects causes a re-
lease of "free" insulin from the pancreas, and a release of "bound" 
insulin, either by inhibiting the binding of pancreatic insulin, or by 
stimulating the dissociation of the circulating insulin complexes. 
Other studies have resulted in similar reports. Lacy (53) 
studied the addition of 100 mg of tolbutamide per ml of normal human 
serum, and found that measurable ILA increased from 100 to 120% 
over control samples. Hasselblatt (54) reported that doses of 22 mg 
of tolbutamide per 100 ml of serum were sufficient to cause a sig• 
nificant release of insulin from serum protein, and at 70 mg per 
100 ml, the effect was maximal. 
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Gundersen (55) was unable to produce any release of com-
plexed serum insulin with tolbutamide incubation, and restated the 
proposition that tolbutamide acts solely on the beta cells of the 
pancreas, to increase the secretion of pancreatic insulin, and that 
it bas no effect on circulating insulin. 
No definitive answer has been agreed upon concerning the 
action of tolbutamide, and studies are in progress in several lab-
oratories to attempt to evaluate the conflicting evidence, and to 
produce concluaive evidence on the true action or actions of the 
drug on insulin release. 
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CHAPTER V 
:MA.TERIALS AND METHODS 
Radioimmunoassay of Insulin 
The radioimmunoassay of insulin was carried out according 
to a modified form of the method of Hales and Randle (56). The 
method use$ an antibody specific to insulin. The insulin in the 
test solution competes with added radioactive insulin for binding 
sites on the antibody. The resulting insoluble insulin-antibody com-
plex is then filtered out, and measured for radio-activity. The level 
of activity is related in an inverse manner to the amowit of insulin 
present in the test solution. 
Reagents 
1. Insulin binding reagent-Wellcome Brand, fMR48, batch 
llK4908, obtained from Amersham/Searle Corporation, Des Plaines, 
Illinois. The commercial product is prepared in the following 
manner. Anti-sera are prepared to insulin (in guinea pigs) and to 
guinea pig serum proteins (in rabbits). After adjustment of the titer 
of an anti-insulin serum, it is diluted in buffer containing EDTA 
(ethylenediamine tetraacetic acid) and mixed with a predetermined 
amowit of the anti-guinea pig precipitating serum. The mixture 
is allowed to react at 4°C for 18 hours and then freeze-dried. 
-31-
When reconstituted to a volume of 8 ml, each vial of the bind-
ing reagent contains guinea pig serum precipitate diluted to 1 in 
16, 000 and 0. 03 M EDTA in Buffer A (see Table II). 
-
The reconstitution of the powdered reagent was carried 
out as follows: to one vial of the powdered reagent, 8 ml of 
deionized distilled water was added carefully, and mixed gently 
to avoid foaming. For the assay, volumes of O. 1 ml were dis-
pensed with an Eppendorf micropipette into 10x75 mm disposable 
culture tubes (Corning #00445). Thus, one vial of the reconstituted 
insulin binding reagent was sufficient for 80 individual samples. 
z. Insulin standards were prepared according to the procedure 
described in Table I. Aliquots of 0. l ml were used in the assay. 
3. Working Solution of Iodinated Insulin - prepared by adding 
0. Z ml of the stock 125-I-inaulin (Amersham/Searle, #IM38, 
batch #65, 0. 1 ug in 1. 0 ml of O. 04!'!f_ phosphate buffer, pH 7. 4, 
O. 6 m!::f merthiolate, and 0. 5% bovine albumin added) to 7. 8 ml 
of Buffer A (See Table ll). 
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Assay Procedure 
Volumes of 0. 1 ml of the insulin binding reagent were dis-
pensed into 10x75 mm culture tubes, kept cold in a bench ice bath. 
Aliquots of O. 1 ml of the unlabeled insulin standards or the un-
knowns solutions, or blanks consisting of Buffer B, were added 
to the culture tubes containing the binding reagent, and the tubes 
were then mixed with a Vortex Jr. Mixer. The tubes were then 
placed in the refrigerator for six hours at 4°C. 
After six hours the tubes are removed from the refrigerator 
and returned to the bench ice bath. Aliquots of 0.1 ml of the work-
ing solution of 125-I-lnsulin are added to the tubes, the tubes are 
mixed, and then returned to the refrigerator for eighteen hours. 
The final composition of a representative set of tubes is given in 
Table Ill. 
At the end of eighteen hours, the tubes are removed from the 
refrigerator and placed in the bench ice bath for processing. A 
microanalysis filtration apparatus is used to collect the precipitated 
insulin-antibody complex (Millipore Microanalysis Filter Holder 
# XX 10 025 03, with Millipore celluloae acetate membrane filters, 
#HAWG 025 00, O. 45 uM, Z5 mm diameter). The membrane filters 
are pre-soaked in cold Buffer C, and applied to the filter holder 
using forceps. The holder is assembled, the line vacuum is applied, 
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and the contents of the first tube le drawn up in a diSPo pipette, 
5 ... 3/4 11 long. The contents are carefully applied to the filter ap-
paratus, and the tube is washed twlce with about one ml of cold 
Buffer C, the washing• being drawn up into the same pipette, and 
applied to the filter. The filter is then washed twice with one ml 
of cold Buffer C, disassembled, and the filter removed with a for-
ceps and scalpel, and transferred immediately to a counting vial. 
A new filter is put in place, the apparatus is reassembled, and the 
next tube is processed in the same manner. After all the tubes 
have been processed in this manner, they are dried for ten minutes 
at l 10°C. After the tubes have cooled to room temperature, 10 ml 
of the ecintillation iluor is pipetted into the vials. The fiuor used 
was Fluor I, described in Table IV. The samples are then placed 
in a Beckman LS-2.50 Liquid Scintillation Counter, allowed to dark 
adapt for two hours, and then counted. In most cases, the samples 
were counted for ten minutes, although longer counts were used in 
instances where the labeled insulin had lost enough of its activity 
through age to warrant a longer count. The gain control was set 
at 360, and the full window isoset was employed, to obtain maximum 
efficiency in the counting. The external standard ratio system of 
the instrument was employed to monitor the relative quenching of 
the samples. and to determine whether or not corrections for 
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quenching would have to be applied to the results. The external 
standard ratio readings reflect the efficiency of the count for each 
individual sample; if there is a considerable variation in the extern-
al standard ratios of the individual samples, then a correction factor 
must be applied to the raw results of the count, to allow for a vary-
ing efficiency in counting the different samples. If the ESR readings, 
however, are uniform, then this reflects the fact that the efficiency 
of the counts is uniform enough to make any correction factor un-
necessary. It was found that the samples were very much uniform 
with respect to the external standard, which meant that no quench 
correction would be necessary. 
One set of replicates was prepared to obtain a control count. 
These tubes were the wash control samples; only iodinated insulin 
and buffer were placed in the tubes. They reflect the degree of 
retention of the free labeled insulin by the filter disc. 
The results of the count were plotted on semilog paper, with 
the net CPM (observed CPM - wash controls) on the logarithmic 
scale, and the insulin concentration on the linear scale. Thus, the 
insulin concentration of any unknown samples could be read directly 
off the graph. 
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TABLE I 
PREPARATION OF INSULIN STANDARDS 
A. Preparation of First Stock Solution (ZOO ug/ml) 
Two mg insulin (Calbiochem, bovine pancreas insulin, 
recrystallized, #40769, lot 53258, B grade, assay ZS uU/mg) 
was weighed into a small tube and dissolved in one ml of 
O. 03M HCl. It was transferred to a ten ml volumetric 
flask and the tube was washed twice with distilled, deionized 
water, the washings being transferred to the flask. Water 
was added to the mark. This solution was dispensed in 
0. 1 ml aliquots into small vials, and stored at -zo0 c. This 
solution was found to be stable several weeks after prepara-
tion. 
B. Preparation of Second Stock Solution (2 ug/ml) 
Two ml of Buffer B (see table 2) was added to one of the 
vials containing 0. l of the first stock solution. After care• 
ful mixing, the solution was transferred to a ten ml volu-
metric flask, the vial washed twice with Buffer B, the wash-
ings transferred to the flask, and the flask filled to the mark 
with Buffer B and mixed. This solution was prepared fresh 
for every assay, and kept at 4°C until used. 
-36-
, 
C. Initial Working Standard (ZO ng/ml) 
. 05 ml of the Second Stock Solution was placed in a 
fifty ml volumetric flask, and diluted to the mark with 
Buffer B. From this solution, a series of standard 
solutions was prepared according to the following table. 
I 
I 
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Table I (cont.) 
TABLE OF WORKING STANDARDS 
INITIAL FINAL CONCEN-
STANDARD WORKING BUFFER INSULIN TRATION 
NUMBER STANDARD (ml)* B ng/ml uU/ml 
1 0.2 9.8 0.4 10 
2 0.2 4.8 0.8 zo 
3 o.z 1.8 z.o 50 
4 1.0 4.0 4.0 100 
5 1. 0 1. 5 8.0 200 
* 500 uU/ml or 20 ng/ml 
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Table II 
BUFFER SOLUTIONS 
Buffer A 40 mM phosphate buffer, pH 7. 4 1 for dilution of 
-
antieera and iodinated insulin. 
Buffer B -
samples. 
Buffer C 
precipitates 
7. 0 gms sodium phosphate monobasic-monohydrate 
0. 25 gms domiphen bromide (Mann Laboratories, 
No. 6405) 
1. 0 gms bovine albumin, Fraction V powder 
(Pentex Biochemicals, Lot 98) 
Sodium Hydroxide, 2N, to pH 7. 4 
Distilled, de-ionized water to 1 liter pH readjusted 
to 7.4 
Stored at 4 °c 
Buffer for dilution of standard insulin and plasma 
9. 0 gms sodium chloride 
Buffer A, to 1 liter 
Stored at 4°c 
High protein content buffer for washing antibody 
39 gms bovine albumin, Fraction V powder 
Buffer A, to 1 liter 
Stored at 4 °c. 
-39-
* See Table I for composition of standards. 
**Initial Working Standard 
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Table IV 
COMPOSITION OF SCINTILLATION FLUORS 
Fluor I - 150 ml ethanol (absolute) 
300 ml J?·dioxane (scintillation grade) 
50 gms naphthalene (recrystallized from ethanol) 
5 gms 2, 5-diphenyloxazole (P. P.O. -Packard, lot #462.7) 
Toluene to one liter, stored in a brown bottle, away 
from direct light. 
Fluor II - 50 gms naphthalene 
5 gms P.P.O. 
e_-dioxane, to one liter 
Fluor Ill - 5 gms P. P. o. 
Toluene to one liter. 
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EXTRACTION OF SERUM FRACTION WITH "BOUND INSULIN" 
ACTIVITY 
A column was packed with Dowex Analytical Grade resin, 
AG50-X8, sodium form, (Bio-Rad Laboratories, lot #5369). The 
resin was first equilibrated with 0. 15 ..!:!. NaCl for three hours. 
It was then packed in a two cm diameter glass column, to a final 
wet volume of 175 ml. After packing, two liters of 0. lSN -
NazHP04 were passed through the column, making the final pH 6. 6. 
100 to 300 ml of pooled human serum (obtained from Veteran's 
Administration Research Hospital, 333 E. Huron, Chicago, Ill.) 
was passed through the column at a rate of 8 ml/minute. After 
passage of the serum, the column was washed with two resin vols 
of 0. 15 ~ NaCl, to remove any contaminating substances, followed 
by elution of the "bound" insulin fraction with one resin volume of 
0. I N NH4 OH. The pH of the eluate was monitored with a Radio-
meter pH meter, and kept at 7. O ±. O. 5 with 2!'.:! H2so4• After 
elution of the "bound" insulin fraction, the eluate was lyophilized at 
pH 7. O, and stored as the dry powder at -lo 0 c. 
After elution of the ''bound 11 insulin fraction, the column could 
be reconstituted by the procedure shown on Table VI. 
~--------------4-2-------------~ 
TABLE V 
EXTRACTION OF BOUND INSULIN FROM SERUM 
Serum 
(100 to 300 ml) 
I 
Dowex 50W-X8 (Na T Cycle) 
175ml Wet Resin Volume 
I 
0.15M NaCl Wash 
(2x Resin Volume) 
I 
Elution of Bound Insulin 
With lrml O.lN NH,oH 
2N H2io' to pH 7.0 .:!:: 0.5 
Lyoprrization 
Stored Frozen As 
Dry Powder 
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TABLE VI 
RECONSTITUTION OF RESIN 
6 Literi H2o 
3 Lite rs 6M NaCl 
I 
H21 to pH 2.7 
2 Lite rs 0.2N Na OH 
I 
H21 to pH 6.0 
1 Liter 0.05r Na 2 HPO. 7H20 
3 Liters 0.15M NaCl 
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CHAPTER VI 
EXPERIMENTAL RESULTS 
Experiment I. First Test of Radioimmunoassar Method for 
Measurement of Insulin Activity 
The purpose of this experiment was to study the accuracy 
and practicality of the radioimmunoassay method as a means for 
measuring true insulin activity. A set of insulin standards was 
prepared, as per Table I. They ranged in concentration from 
10 to 500 uU /ml of insulin. The working solutions of labeled 
insulin and insulin binding reagent were prepared as discussed in 
Materials and Methods. The samples were counted for ten minutes, 
with Fluor I as the scintillation medium. The results are listed 
in Table Vll. 
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Table VII 
RESULTS OF EXPERIMENT I 
Insulin 
Concentration Observed CPM 
uU/ml (Range of 3 Replicates) Mean CPM 
0 2404-3338 2831 
10 2069-2610 Z332 
~; 20 2074-2397 2198 
50 2170-2218 2190 
100 2261-2323 2301 
,, 200 1886-2195 2006 
I ~.·· 
., 
500 1861-1956 1905 
Std. Insulin Blank 328-338 333 
Buffer Blank 322-352 335 
Wash Control 1139-1726 1462 
~\\' 
Fluor Bkg. 75-84 80 
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The range of counts for the individual replicates in 
Experiment I was so great that no accurate correlation between 
observed CPM and insulin concentration could be made. The 
values for different concentrations often overlapped, with the 
only reliable readings being those corresponding to the buffer and 
insulin blanks and the filter blank. The range in the wash control 
samples (1138.6 to 1726.4) indicated that a problem might be 
present in the separation of the free and antibody-bound insulin. 
In order to determine whether these results were valid, or 
whether the variation was due to some error in the experimental 
procedure, it was decided to repeat the experiment, this time 
using five replicates instead of three. 
Experiment II - Test of Radioimmunoassay Method for Measurement 
of Insulin Activity, Five Replicates per Sample 
This experiment was essentially a duplication of the first 
experiment, with the one exception being the increase from three 
to five replicates per sample. 
All reagents were prepared fresh. The results are listed 
in Table VIII. 
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Insulin 
Concentration 
uU/ml 
0 
10 
20 
50 
100 
zoo 
Wash Control 
Membrane Blank 
*Not Calculated 
Table Vill 
RESULTS OF EXPERIMENT II 
Observed CPM Standard 
Mean of 5 Replicates Deviation 
3111 388 
2894 
* 
2833 * 
3029 
* 
2956 
* 
2595 
* 
1051 387 
392 27.5 
From calculation of the standard deviation of the control 
samples (s. d. =387) and of the tubes with the highest activity, 
those containing no unlabeled insulin (s.d. = 388), it was again 
found that a great variability exists in the replicates. With such 
a degree of overlap, the assay would be unsuitable for any accurate 
determination of insulin concentration, unless a large number of 
replicates was run for each sample, to increase the statistical 
significance of the results. 
Since the variability existed in the wash control samples, 
which are really indicative of both the efficacy of the wash pro-
cedure and of the retention of free labeled insulin by the membrane 
filters, these two factors were considered to be possible sources 
of the problem. After the first experiment, in which the same 
variability in the replicates was exhibited, the subsequent wash 
procedures were performed very carefully, to avoid any possibility 
of non-uniform washing leading to the apparent non-uniform reten-
tion of the free labeled insulin. When this had no efiect, the mem-
brane filters themselves were considered to be the only other 
possible source of error. 
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Experiment m .. Comparison of Two Cellulose Acetate Membrane 
Filters With Respect to Retention of Free, 
Labeled Insulin 
Since the membrane filters were suspected of a lack of 
uniformity in retention of free labeled insulin, this experiment 
was designed to study the retention properties of the filters used 
for the first two experiments, and to study the same properties 
of similar filters from another source, to see if a change in 
filters could alleviate the difficulty. 
Filters Used: 
l) Millipore cellulose acetate membrane filters, 
pore size 0.45 um, No. HAWG02500, ZS mm diameter. 
Z) Gelman Metricel cellulose acetate membrane filters, 
pore size 0. 45 um, No. GA-6, I-inch diameter. 
Suf!icient tubes were set up for five replicates each of Milli-
pore and Gelman filters, with and without the addition of 0. 1 ml of 
125-I-insulin. All filters were soaked in cold Buffer C, then placed 
in the filter holder and washed with 5 ml of cold Buffer C. All 
filters were then placed in counting vials, and dried for 10 minutes 
at 110°c. 10 ml of Fluor I was then added to each vial, and after 
one hour of dark adaptation, they were counted in the usual manner. 
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A) 
Table IX 
RESULTS OF EXPERlMENT III 
Gelman filters, no labeled insulin added 
CPM 
306.1 
310.6 
361.1 
355.7 
335.l 
Mean 333. 7 Std. Dev. Z2. 9 
B) Millipore Filters, no labeled insulin added 
CPM 
436.7 
395.0 
389.0 
364.5 
376.0 
Mean 392. 2 Std. Dev. 27. 5 
C) Gelman filters, 9. I ml 125-I-insulin added 
CPM 
568.6 
481. 2 
508.8 
521. 8 
543.l 
Mean 524. 7 Std. Dev. 32. 3 
D) Millipore Filters, O. 1 ml 125-1-insulin added 
CPM 
1273.8 
1586. 4 
1572.4 
1876.2 
2226.9 
Mean 1707.l Std. Dev. 360.3 
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The results of Experiment III (depicted graphically in 
Figure V) clearly indicated that the variability of replicates 
was due to the random retention of iodinated insulin by the 
1Hllipore membrane filters, apparently due to a lack of uniformity 
of pore size. The Gelman filters were much more suitable, due 
to the much lower retention of labeled insulin, and the uniformity 
of the retention, as indicated by the much smaller standard de-
viation (Millipore 360. 3, Gelman 32. 3). For this reason, Gelman 
filters were used in all subsequent experiments, to assure better 
controls. 
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E~~periment IV - Radioimmunoa.ssay of Insulin: Preparation of 
Standard Curve Using Fluor II 
Once the problem of variability of the replicates had been 
solved, another set of standards was prepared, in order to pre-
pa.re a standard curve. All stock solutions of buffers, insulin 
standards, labeled insulin, and insulin binding reagent were pre-
pared fresh. The working standards were prepared to include 
smaller increments than were used previously in order to better 
define the standard curve. As in the previous experiments, five 
replicates were prepared for each sample. The samples were run 
as before, using Gelman instead of Millipore filters. A change 
in the scintillation fiuor was introduced, and Fluor ll (see Table 
IV) was not used. Fluor II is a standard scintillation medium, 
and was favored over Fluor I because of its relative simplicity and 
smaller danger of contamination. When equal amounts of iodinated 
insulin were added to nuor, I and Fluor II, there was no appre-
ciable change in the counting characteristics. 
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Table X 
WORKING STANDARDS. EXPERThtlENT IV 
Initial 
Working Insulin 
Standard* Buffer B Cone entration 
Standard ff (ml) (ml) uU/ml ng/ml 
l 0.2 9.8 10 0.4 
2 0.2 4.8 20 0.8 
3 o.z l. 8 50 2.0 
4 1. 0 6.5 75 3.0 
5 l. 0 4.0 100 4.0 
6 2.0 5.5 150 6.0 
7 1.0 1.5 200 8.0 
8 5.0 500 20.0 
* 500 uU/ml. or 20. 0 ng/ml 
-ss .. 
~,. 
, 
Insulin 
Concentration 
(uU/ml) 
0 
10 
zo 
50 
75 
100 
150 
zoo 
500 
Wash Control 
Fluor Bkg. 
Table XI 
RESULTS OF EXPERIMENT IV 
Net CPM (Obs. -wash control) 
(Mean of Five Replicates) , 
3863 
15Z4 
1518 
1136 
855 
635 
600 
456 
2.57 
359 (Obs.) 
89 
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Standard 
Deviation 
Z21 
184 
122 
53 
48 
26 
55 
38 
48 
17 
8 
The results of Experiment IV are shown in Table XI. 
With the introduction of the Gelman membrane filters into the 
assay system, the variability in the retention of free labeled 
insulin was alleviated. This is indicated by the wash control 
samples, which remained at a workable level (359 CPM). This 
reading was used as the control level for all samples, and the 
observed activity of all other samples was corrected by subtracting 
this amount, to account for the retention of free labeled insulin 
by the filters. 
The standard curve prepared from this experiment is 
I 
I 
shown in Figure VI. The net CPM is plotted on the logarithmic 
sc.ale. From this curve, the concentration of insulin in any 
unknown sample can quickly and easily be found, by comparing 
the activity of the unknown sample to the standard curve. 
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FIGURE VI 
10,000 
• 
0 
\ 
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Substitution of Polyvinylpyrrollidone for Albumin in Buffer 
Solutions 
In the portion of this paper dealing with insulin antagonism, 
the existence of an insulin antagonist in albumin preparations 
was discussed. To review briefly, Vallance-Owen and Hurlock(41) 
have done considerable work in this field, and they report com-
plete antagonism of 1000 uU I ml of insulin, in vitro, by standard 
preparations of the albumin fraction of normal and diabetic serum, 
in concentrations above 3. 5%. They further postulate, on the 
basis of characterization studie.$ of this "synalbumin 11 insulin 
antagonist, that the B- chain of insulin itself may be implicated 
as the antagonistic factor in the albumin preparations (42). 
Albumin (Fraction V powder) is present in all buffer solu-
tions used in the assay, in concentrations ranging from 0. 1% to 
3. 9%. Because of the above mentioned poesibility of insulin 
antagonism of albumin preparations, it was considered prudent 
to seek a substitute for albumin, to eliminate the possibility of 
interference of the albumin antagonist in the assay, and to assure 
that the assay is picking up all the antibody-reactive insulin in 
the samples, and that none of it is being rendered unreactive by 
the "synalbumin" antagonist. 
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In the choice of a substitute for albumin, several factors 
had to be considered. Ideally, the substitute should resemble al-
bumin closely, with respect to molecular weight, solubility, and 
solubility-enhancement properties. Such a material is polyvinyl-
pyrrolidone (PVP). 
unit is: 
It is a polymeric substance, whose basic 
lNAo 
I 
-CH-CH~ 
It resembles albumin in its physical properties, but does not have 
the same chemical properties associated with albumin. It is avail-
able in several average molecular weights, 40, 000 being the closest 
to that of albumin. It is used medically as a plasma substitute. 
in 3. 5% solution, in cases of hemorrhagic shock. 
For these reasons, plus the fact that it can be stored at 
room temperature and is much more easily dissolved in water than 
is albumin, PVP was chosen as a replacement for bovine albumin 
in all buffer solutions used in the assay. It was used in the same 
concentration, and the buffers were prepared and stored under 
the same conditions. In all references to the buffers, the terms 
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Al, Bl and Cl will be used to signify the new preparations, 
I 
'ii! 
11 
I 
identical to buffers A , B and C with the one exception being the 
, change from albumin to PVP. 
The new buffers were found to have no detrimental effects 
on the accuracy or sensitivity of the assay, (aee Experiment V), 
and their use eliminates the danger of interaction of the "synal-
bumln 11 antagonist with the insulin in the samples. 
i 
Ii 
11,___ ____ ______. 
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Experiment V • Release of Bound Insulin by Tolbutamide, 
Assayable by Radioimmunoaasay 
Bound insulin extracts were prepared from 500 ml of human 
serum, the resulting lyophilized resin eluate weighing 1. 347 grams. 
A solution of this resin eluate in Buffer Bl, and sodium tolbutamide 
in Buffer Bl, and appropriate controls were incubated for two hours 
at 37°C. The composition of the incubation mixtures is shown in 
Table XII. Aliquots from these incubation mixtures were assayed, 
along with insulin standards prepared from a standard human 
insulin preparation. The insulin standards are described in Table 
XIII. The buffers used were those prepared with PVP. The re• 
sults of the experiment are shown in Table XIV, and graphically 
in Figure VII. 
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Table Xll 
COMPOSITION OF INCUBATION MIXTURES, EXPERIMENT V 
I Sodium Resin Eluate Tolbutamide* 
Tube # ~z. 78 mg/ml) (0. 037 M) Buffer Bl 
1-4 1 ml 1 ml 
5 1 ml 1 ml 
* as Sodium Orinaae, Upjohn, Lot #11584-4 
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TABLE XIII 
PREPARATION OF HUMAN INSULIN STANDARDS, EXPERIMENT V 
1. Standardized human insulin (Amersbam/Searle, Batch 9228, 
2. 10 mU). Dissolved in 2 ml of Buffer Bl, made up to 
10 ml with additional Buffer Bl. This solution contains 
I 210 uU/ml or 8. 4 ng/ml of insulin activity. 
I 
I 
J 
I 
2. Working Standards. 
Reconstituted Final Insulin 
Std. Insulin Buffer Bl Cone entration 
(ml) (ml) uU/ml ng/ml 
z.o 210 8.4 
2.0 z.o 105 4.2 
2.0 6.0 52.5 2. 1 
1. 0 9.0 21. 0 0.84 
o.s 9.5 10.5 0.42 
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I 
Insulin I Concentration (uU/ml) 
210 
105 
52.5 
I Zl.O 
I 
l 10.5 
i 0 l Inc.Mix 1 I I 
Inc.Mix Z 
Inc.Mix 3 
Inc.Mix 4 
Inc.Mix 5 
Wash Control 
FlUOl" Bkg. 
Table XIV 
RESULTS OF EXPERIMENT 
Observed CPM 
(Range of Three 
Replicates) 
693-715 
1016-1034 
1420-1514 
1989-2064 
2439-2589 
2755-2999 
615-647 
603-661 
637-730 
679-746 
2615-2887 
321-342 
97-103 
v 
Mean Net CPM 
(Obs. -Wash Control 
374 
697 
1147 
1703 
2157 
2523 
300 
299 
368 
389 
2404 
0 
99. 9 (obs.) 
I 
10,000 
~ 
a. 
u 
1000 
40 80 
FIGURE 7 
120 160 
)lU/ml 
:<304 .... 
;--~ 
PROJECTED 
200 240 
I 
280 
The results 0£ Experiment V are very significant, in 
that although the radioimmunoassay picked up only 2uU /ml of 
insulin activity in the sample consisting of bound insulin extract 
in Buffer Bl, the samples incubated with the oral hypoglycemic 
compound tolbutamide showed a very significant amount of 
insulin activity, averaging 244uU/ml of insulin activity for the 
four samples. These activities correspond to actual concentra-
tions of 0. 7 uU of free insulin per mg of the reain extract in 
the absence of the oral agent, and 87. 8 uU of free insulin per 
mg of the extract in the presence of tolbutamlde. 
The activity reported here corresponds well with the 
values of 30-100 uU/mg reported by Antontades(Z5), using the 
rat diaphragm assay in the presence of adipose tissue extracts. 
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Summary and Conclusions 
The determination of insulin activity by the radioimmuno-
assay method is a relatively recent development. It has many 
limitations, such as the necessity of access to automated radio-
activity counting devices, a tool not available to many laborator-
ies. Coupled with this is the necessity of maintaining a supply 
of lnsulin-I-125, another rather costly factor contributing to the 
limited use of the method. The assay, in the form first used in 
our own laboratories, was not sufficiently accurate for an exact 
determination of insulin activity, without the use of a minimum 
of five replicates for each sample. The modifications undertaken 
in our laboratory have alleviated this somewhat. 
In the first place, our experiments have shown that the 
choice of the proper membrane filter, among seemingly identical 
products, is extremely critical to the precision of the assay. For 
in delivering the assay mixture onto the filtering device, a signifi-
cant amount of free iodinated insulin is retained by the filter. 
This amount must be kept both minimal and uniform if the assay 
is to be relied upon Variations in pore size of the filter apparently 
contribute to this retention and only filters whose pore character-
istics are uniform can be used in the assay. For this reason, it 
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II. '''1 
1
1: 
111 
I 
would be prudent to test the pore characteristics of each batch 
I, 
of filters to be used in the assay, in a manner similar to that 
used in Experiment In. 
Secondly, the use of polyvinylpyrrolidone instead of al-
bumin in the buffer solutions is recommended, as a safeguard 
against the exhibition of any "synalbumin" insulin antagonism by 
the albumin. This substitution has practical value in addition 
to the safeguard described above. It allows for greater ease of 
preparation and handling of the buffers, and reduces the cost of 
the assay somewhat. PVP has been used successfully in our 
laboratory as a buffer component, with no discernible adverse 
effects on the precision or accuracy of the assay. It use is one 
more assurance that the assay of insulin in this manner is truly 
representative of all available chemically intact insulin in the 
samples. 
The third modification of the assay is centered around 
the determination of radioactivity of the samples. The scintilla-
tion "cocktail" originally used in the assay, and that recommended 
for counting samples of this type by Amersham/Searle Radiochem• 
ical Center, was found to be unduly complex, and suitable results 
were obtained with fluors consisting o! either PPO, naphthalene, 
and e,-dioxane, or PPO and toluene. These fluors are more quickly 
L 
stabilized, and because of their relative simplicity, they are 
advantageous from the standpoint of lower chance of contamination. 
The last part of this thesis deals with the adaptation of 
the radioimmunoassay of insulin, as modified in our laboratories, 
to the determination of the actual insulin content of "bound" insulin 
extracts, obtained by ion-exchange separation from human serum. 
The fact that the assay showed insignificant amounts of insulin 
actlvity in the extracts in the absence of tolbutamide, and quite 
significant amounts in the presence of tolbutamide lends credence 
to the position taken by Antonia.des, the position that the material 
he refers to as ''bound" insulin truly contains chemically intact 
insulin. The major point to remember is that the other assay 
methods for insulin depend on its biological activity, and are sub-
ject to the presence or absence of many factors, known and unknown, 
which may enhance or impair the biological function of insulin. 
The radioimmunoassay method depends on the chemical conforma• 
tion of the insulin molecule itself and nothing but chemically intact 
insulin can bind to an anti-insulin antibody and produce the results 
obtained by this method. 
The release of the insulin from the "bound 11 form by the 
oral hypoglycemic agent, tolbutamide, reported by Antoniades (52), 
Lacy (53), and Hasselblatt (54), was observed in our laboratories, 
using the radioimmunoa.ssay method. This release is considered 
to be further evidence of the dual role of tolbutamide as a thera-
peutic agent in diabetes; as described in 1963 by Antoniades (52). 
Aside from the stimulation of insulin release from the pancreas 
observed with tolbutamide, it may act to increase the rate of 
utilization of the inactive or "bound" form of the circulating hor-
mone in insulin-dependent diabetics. 
The modifications of the radioimmunoa.ssay method for 
determination of insulin, and the dernonstration of true insulin 
activity in "bound 11 insulin extracts in the presence of tolbutamide, 
lend support for the use of the radioimmunoassay method as a 
major tool in the study of two important factors in diabetes 
mellitus: first, the role of inactive or ''bound" insulin in the 
diabetic state; second, the role of tolbutamide as an important 
therapeutic tool in the maintenance of diabetics, and the under-
standing of the full mechanism of action of the agent ln the maxi-
mum utilization of endogenous insulin in the diabetic patient. 
-71-
~ 
' 
1 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
BIBLIOGRAPHY 
Stetten, D., Jr. and Boxer, G. E., "Studies in Carbohy-
drate Metabolism, III. :Metabolic Defects in Alloxan 
Diabetes, 11 J. Biol. Chem. 156: 231-242 (1944) 
Chaikoff, I. L.. "lvfetabolic Blocks in Carbohydrate :Metabolism 
in Diabetes, 11 Harvey Leet. 1951-1952, 47:99 (1953) 
Chernick, S.S., lviasoro, E. J., and Cha.ikoff, I. L., "The 
In Vitro Glucose Response To Fatty Acids, 11 Proc. 
Soc. Exp. Biol. and }v~ed. 73: 348-352 ( 1950) 
Lossaw, N.J., Brown, C.W., Jr., and Cb.aikoff, I.L., "The 
Action of Insulin in Sparing F&tt4 Acid Oxidation: 
A Study with Palmitic Acid-1-cl and Octanoate-l-cl4, 11 
J. Biol. Chem. 220: 839-850 (1956) 
Castiglioni, C., "Proteins and Lipoproteins in Diabetes," 
Arch. Uruguay Ued. 51: 355-368 (1958) 
Rosenthal, S. R., "Studies in Atherosclerosis: Chemical Ex-
perimental and Morphologic. I and II. Roles of 
Cholesterol Metabolism, Blood Pressure and Structure 
of the Aorta, the Fat Angle of the Aorta and the Infil• 
tration-Expression Theory of Lipid Deposit, "Arch. 
Pathol. 18: 473-506 (1934) 
Banting, F. a.. "The History of Insulin, II Edin. Med. J. 
~: 1·18 (192.9) 
Bornstein, J. and Lawrence, R. D. , "Plasma Insulin in 
Human Diabetes Mellitus," Brit. Med. J. 2: lp4l-1544 
(1951) 
Vallance-Owen, J. , and Hurlock, B. , "Estimation of Plasma 
Insulin by the Rat Diaphragm Method, 11 Lancet 1: 68-70 
(1954) 
Vallance-Owen, Jr., Hurlock, B. 1 and Please, N. W. 
"Plasma-Insulin Activity in Diabetes Mellitus Measured 
by the Rat Diaphragm Technique, " Lancet 2: 
583-587 ( 1955) 
-72-
f 
11. Seltzer, H. S., and Smith, W. L., "Plasma Insulin Activity 
After Glucose," Diabetes 8: 417-423 (1959) 
12. Jvf.artin, D.B., Renold, l:.~.,and Dagenais, Y.~1.t., "An 
Assay for Insulin·i.1te Activity Using Rat Adipose 
Tissue, " Lancet 2:76-77 (1958) 
13. Steinke, J., Soeldner, S., Camtrini-Davaloe, R. l~ .. , and 
Renold, A. E., "Studies on Serum Insulin-Like Activity 
(ILA) in Prediabetes and Early Overt Diabetes," 
Diabetes lZ: 502-507 (1963) 
14. Moloney, P. J. and Coval, M., "Antigenicity of Insulin: 
Diabetes Induced by Specific Antibodies," 
Biochem. J. 59: 179-185 ( 1955) 
15. Slater, J.D.H., Samaan, N., Fraser, R., Stillman, D., 
"Immunological Studies with Circulating Insulin, 11 
Brit. Med. J. 1: 1712-1716 (1961) 
16. Samaan, N. Fraser, R., and Dempster, W.J., "The 'Typical' 
and 'At)rpical' Forms of Serum Insulin, 11 Diabetes lZ: 
339-348 (1963). 
17. Froesch, Burgi, H., Ramseier, E. B., Bally, P., and 
Labhart, A., "Antibody-Suppressible and Non-suppres-
sible Insulin-Like Activities in Huma.n Serum and their 
Physiologic Significance. An Insulin Assay with Adipose 
Tissue of Increased Precision and Specificity. " 
J. Clin. Invest. 4Z:l816-1834 {1963) 
18. Keen, H., 11Properties of Human Albumin," Diabetes 12: 
406-413 (1963) 
19. Cameron, J. S., Keen, H. • and lv1.enzinger, G., 11Insulin 
Activity of Normal Plasma and Plasma Acid-Ethanol 
Extracts," Lancet 1: 74-76 (1964) 
20. Yalow, R.S., and Berson, S.A., "Immunoassay of Endogenous 
Plasma Insulin in }:1an," J. Clin. Invest. 39: 
1157-1175 (l9Ul) 
-73-
21. Antoniades, H. N. , Beigelman, P. M., Pennell, R. B. , 
Thorne, G. W., and Oncley, J. L., ''Insulin-Like 
Activity of Human Plasma Constituents, m," 
Metabolism 7: 266-268 (1958) 
22. Antoniades, H.N., Bougas, J.A., Camerini-Davalos, R. and 
Pyle, H.M., "Insulin Regulatory Mechanisms and 
Diabetes 1v1ellitus," Diabetes 13:230-239 (1964) 
23. Shaw, \Y.N., and Shuey, E.Vi., "Insulin .. Like Activity in 
Human Serum, 11 Biochemistrv 2:2f6-2.90 (1963) 
24. Antoniades, H. N., Beigelman, P., Tranquada, R., and 
Gundersen, K., "Studies on the State of Insulin in 
Blood: "Free" Insulin and Insulin Complexes in Human 
Sera and Their In Vitro Biological Properties, " 
Endrocrlnology 69: 46-54 (1961) 
25. Antoniades, H. N., Huber, A., Boshell, B., Saravia, C., 
and Gershoff, S., "Studies on the State of Insulin in 
Blood: Properties of Circulating "Free 11 and "Bound 11 
Insulin, " Endocrinology 76: 709-721 ( 1964) 
26. Antoniades, H. N., Huber, A., and Gershoff, S., "Bound" 
Insulin; In Vivo and In Vitro Biologic Activity, 11 
Diabetologia 1: 195-200 (1965) 
2 7. Antoniades, H. N., and Gundersen, K., "Studies on the State 
of Insulin in Blood: Dissociation of Purified Human 
Blood Insulin Complexes by Incubation with Adipose 
Tissue Extracts In Vitro, " Endocrinolosr 68: 36-42 ( 1961) 
28. Gershofi, S., Huber, A., and Antoniades, H.N., "Responses 
of Obese-Hyperglycemic 1'Hce and Normal Mice to 
"Bound" and Crystalline Insulin," ?vfetabolism 15: 
325-329 (1966) 
29. Antoniades, H.:tvf., and Gershoff, S., "Bound' Insulin; 
Biologic Effects in Intact, Hypophysectomized or 
Adrenalectomized Rats Following Intravenous Ad-
ministration," Endrocrbmlogy 78: 1079-l081 (1966) 
r 
30. 
31. 
32. 
33. 
34. 
35. 
36. 
37. 
38. 
Antoniades, H~N., "Bound" Insulin: Further Purification 
and In Vivo Biologic Activity in Ra.ts, 11 
Vox Sanguinis 13: 49-50 (1967) 
Antoniadee, H.N., "Studies on the State of Insulin in Blood: 
The State and Transport of Insulin in Blood," 
Endocrinology 68: 7-16 (1961) 
Gundersen, K., and Antoniades, H. N., "Biological 
Activity of Blood Insulin Complexes Examined 
by Rat Diaphragm Tissue Assay, 11 Proc. Soc. 
Expl. Med. 104: 411-413 (1960) 
Antoniades, H.N., "Hypoglycemic Effect of Adipose Tissue 
Extracts in Adrenalectomized Rats, " Lancet 1: 
602-604 ( 1967) 
Antoniades, H. N., "Studies on Circulating Free and Bound 
Insulin, 4lst Annual Meeting of Japan Endocrinologi-
cal Society, Folia Endocrinologia Jaeonica 44: 
440-54 ( 1968) 
Vallance-Owen, J., "Insulin Antagonists, u Brit. Med. Bull. 
16: 214-218 (1960) 
-
Bodo, R. C., de and Al tzuler, N., "Insulin Hypersensitivity 
and Physiological Insulin Antagonists, ., Physiol. 
Review 38:389·445 (1958) 
Fraser, R., "Endocrine Disorders and Insulin Action," 
Brit. Med. Bull. 16 :24Z-Z46 ( 1960) 
Vallance-Owen, J., "Insulin Antagonists, 11 in Diabetes 
Mellltus, Ed., L.J.P. Duncan, University Press, 
Edinburgh, 1966, p. Zl-Z. 
39. Hales, C. N. • and Randle, P.J., "Effects of Low Carbohydrate 
Diet and Diabetes Mellitus on Plasm.a Concentrations 
of Glucose, Nonesterified Fatty Acid, and Insulin Dur-
ing Oral Glucose Tolerance Tests," Lancet 1: 
790-794 (1963) 
40. Randle, P.J., Garland, P.B., Hales, C.N., andNewsholme, 
E. A., "The Glucose-Fatty Acid Cycle. Its Role in 
Insulin Sensitivity and the Metabolic Disturbances of 
II • 
41. Vallance-Owen, J., and Hurlock, B., "Estimation of Plasma 
Insulin by the Rat Diaphragm Method, 11 Lancet 1: 
68-70 (1954) 
4Z. Vallance-Owen, J., and Lilley, 11. D., "An Insulin Antagonist 
Associated with Plasma-Albumin, " Lancet 1: 804-806 
( 1961) 
43. Alp, H. , and Recant, L., "Effect of the Insulin Inhibitory 
Albumin Fraction from Normal and Diabetic Subjects 
on Adipose Tissue," Metabolism 13: 609-619 (1964) 
44. Ensinck, J. W., Mahler, R. J. • and Vallance-0.Ven, J. 
"Antagonism of Insulin Action on Muscle by the Al-
bumin-Bound B-Chain of Insulin," Biochem. J. 94: 
150-159 (1965) 
45. Ensinck, J., Coomb, G., Williams, R., and Vallance-Owen, 
J., "Studies in Vitro of the Transport of the A and B 
Chains of Insulin in Serum," J. Biol. Chem. Z39: 
3377-3384 (1964) 
46. Frank E., Nothman, M., and Wagner, A., "tJber synthetisch 
dargstelle Korper unit insulinartiger Wirkung auf den 
diabetischen," Klin. Wchnschr. 5: 2100-2107 (1926) 
47. Graham, G., and Linder, G. C., "The Use of Synthalin in 
the Treatment of Diabetes Mellitus," Quart J. Med. 21: 
509-521 (1928) 
48. Janbon, M., Chaptal, J., Vedel, A., and Schaap, E'• 
Montepellier Med. 441: 21-22 (1942) 
49. Willia.ms, R.H., Pollen, R.H., Tanner, D. C., and Barnes, 
R.H., "Oral Antidia.betic Therapy, 11 Ann. Int. Med. 51: 
1121 (1959) 
50. Yalow, R. S., and Berson, S. A., "Plasma Insulin Concen-
trations in Nondiabetic and Early Diabetic Subjects. 
Determinations by a new Sensitive lmmuno-Assay 
Technic, 11 Diabetes 9: 254-261 (1960) 
... , 
II 
51. Salans, L.B., and Reaven, G. N., "Effect of Oral Hypogly-
cemic Agents on Serum Insulin-Like Activity of 
Patients with Various Degrees of Carbohydrate Intol-
erance, 11 Metabolism 14: 26-32 (1965) 
52. Antoniades, H. N., "Insulin-Regulatory Mechanisms and 
Diabetes Mellitus: Effect of Tolbutamide on the 
Insulin-Regulatory Mechanisms, 11 New Eng. J. Med. 
269: 386-390 ( 1963) 
-
53. Lacy, P. E., "The Effects of Tolbutamide on Beta Cells and 
Some Insulin-Like Activity in Vitro, " Diabetes 11 
(Supp.): 1-2 ( 1962) 
54. Hasselblatt, A., "Liberation of Insulin Bound to Serum Protein 
by Tolbutamide," Metabolism 12:302-310 (1963) 
55. Gundersen, K., "Effect of Tolbutamide on "Free 11 and "Com-
plexed" Serum Insulin," Diabetes 15: 663-667 (1966) 
56. Hales, C. N., and Randle, P. J., "Immunoassay of Insulin 
with Insulin Antibody Precipitate, " Biochem J. 88: 
137 (1963) 
-77-
" 
APPROVAL SHEET 
The thesis submitted by Ronald J. Przybyla has been read 
and approved by two members of the faculty of the Stritch School 
of Medicine. Loyola University. 
The final copies have been examined by the director of the 
thesis and the signature which appears below verifies the fact that 
any necessary changes have been incorporated. and that the thesis 
i• now given final approval with reference to content, form, and 
mechanical accuracy. 
The thesie is therefore accepted in partial fulfillment of 
the requirements for the Degree of Master of Science. 
·· ate 
